# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, ...
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Che...
According to Benzinga Pro data, during Q2, Celsion (NASDAQ:CLSN) posted sales of $125 thousand. Earnings were up 42.31%, but Ce...
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -...
Celsion (NASDAQ:CLSN) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.12) by 22...
Celsion (NASDAQ:CLSN) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors ne...
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Celsion (NASDAQ:CLSN) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors n...